Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SNY
SNY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SNY News
Recursion Pharmaceuticals Expands Partnership with Citeline to Enhance AI Drug Discovery
4h ago
Yahoo Finance
Sanofi's COVID-19 Vaccine Shows Better Tolerability than Moderna's
20h ago
NASDAQ.COM
Trump Nominates Erica Schwartz as CDC Director
2d ago
seekingalpha
Taiho Ventures Celebrates 10th Anniversary with Strong Track Record
4d ago
Yahoo Finance
Dupixent Approved by EU for Pediatric CSU Treatment
6d ago
NASDAQ.COM
European Commission Approves DPREMIUM
6d ago
Yahoo Finance
Dupixent Approved in EU for Children with CSU
6d ago
seekingalpha
Dupixent Approved by EU for Pediatric CSU Treatment
6d ago
NASDAQ.COM
Sanofi and Regeneron's Dupixent Receives EU Approval as the First Targeted Treatment for Young Children with Chronic Spontaneous Urticaria
6d ago
moomoo
Sanofi's Lunsekimig Shows Promise in Phase 2 Trials for Respiratory Conditions
Apr 07 2026
NASDAQ.COM
Sanofi's Lunsekimig Achieves Key Clinical Trial Success
Apr 07 2026
seekingalpha
Sanofi's Lunsekimig Phase 2 Trials Show Promising Results
Apr 07 2026
NASDAQ.COM
Sanofi Receives EU Authorization for Rezurock in Chronic GVHD
Mar 31 2026
NASDAQ.COM
Sanofi's Rezurock Receives Conditional EU Approval
Mar 31 2026
NASDAQ.COM
Sanofi's Amlitelimab Phase 3 Data Shows Promising Efficacy
Mar 30 2026
seekingalpha
FDA Accelerates Biosimilar Drug Development and Approves New Treatments
Mar 30 2026
NASDAQ.COM
Show More News
